Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Estlin, EJ; Pinkerton, CR; Lewis, IJ; Lashford, L; McDowell, H; Morland, B; Kohler, J; Newell, DR; Boddy, AV; Taylor, GA; Price, L; Ablett, S; Hobson, R; Pitsiladis, M; Brampton, M; Clendeninn, N; Johnston, A; Pearson, ADJ
   A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation
   BRITISH JOURNAL OF CANCER
   
   E.J. Estlin et al., "A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation", BR J CANC, 84(1), 2001, pp. 11-18
2. PORTER D; BODDY A; THOMAS H; LIND M; NEWELL D; CALVERT AH; ROBSON L; BRAMPTON M; ABRAHAMSEN D; WINOGRAD B
   ETOPOSIDE PHOSPHATE INFUSION WITH THERAPEUTIC DRUG-MONITORING IN COMBINATION WITH CARBOPLATIN DOSED BY AREA-UNDER-THE-CURVE - A CANCER-RESEARCH CAMPAIGN PHASE I II COMMITTEE STUDY/
   Seminars in oncology
   
   D. Porter et al., "ETOPOSIDE PHOSPHATE INFUSION WITH THERAPEUTIC DRUG-MONITORING IN COMBINATION WITH CARBOPLATIN DOSED BY AREA-UNDER-THE-CURVE - A CANCER-RESEARCH CAMPAIGN PHASE I II COMMITTEE STUDY/", Seminars in oncology, 23(6), 1996, pp. 34-44
3. BLEEHEN NM; NEWLANDS ES; LEE SM; THATCHER N; SELBY P; CALVERT AH; RUSTIN GJS; BRAMPTON M; STEVENS MFG
   CANCER-RESEARCH CAMPAIGN PHASE-II TRIAL OF TEMOZOLOMIDE IN METASTATICMELANOMA
   Journal of clinical oncology
   
   N.M. Bleehen et al., "CANCER-RESEARCH CAMPAIGN PHASE-II TRIAL OF TEMOZOLOMIDE IN METASTATICMELANOMA", Journal of clinical oncology, 13(4), 1995, pp. 910-913
4. LEDERMANN JA; HOLDEN L; NEWLANDS ES; BEGENT RHJ; RUSTIN GJS; BAGSHAWE KD; BRAMPTON M
   THE LONG-TERM OUTCOME OF PATIENTS WHO RELAPSE AFTER CHEMOTHERAPY FOR NONSEMINOMATOUS GERM-CELL TUMORS
   British Journal of Urology
   
   J.A. Ledermann et al., "THE LONG-TERM OUTCOME OF PATIENTS WHO RELAPSE AFTER CHEMOTHERAPY FOR NONSEMINOMATOUS GERM-CELL TUMORS", British Journal of Urology, 74(2), 1994, pp. 225-230
5. BLEEHEN NM; CALVERT AH; LEE SM; HARPER P; KAYE SB; JUDSON I; BRAMPTON M
   A CANCER-RESEARCH CAMPAIGN (CRC) PHASE-II TRIAL OF CB10-277 GIVEN BY 24-HOUR INFUSION FOR MALIGNANT-MELANOMA
   British Journal of Cancer
   
   N.M. Bleehen et al., "A CANCER-RESEARCH CAMPAIGN (CRC) PHASE-II TRIAL OF CB10-277 GIVEN BY 24-HOUR INFUSION FOR MALIGNANT-MELANOMA", British Journal of Cancer, 70(4), 1994, pp. 775-777
6. OREILLY SM; NEWLANDS ES; GLASER MG; BRAMPTON M; RICEEDWARDS JM; ILLINGWORTH RD; RICHARDS PG; KENNARD C; COLQUHOUN IR; LEWIS P; STEVENS MFG
   TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS
   European journal of cancer
   
   S.M. Oreilly et al., "TEMOZOLOMIDE - A NEW ORAL CYTOTOXIC CHEMOTHERAPEUTIC AGENT WITH PROMISING ACTIVITY AGAINST PRIMARY BRAIN-TUMORS", European journal of cancer, 29A(7), 1993, pp. 940-942